Financials data is unavailable for this security.
View more
Year on year Pieris Pharmaceuticals Inc grew revenues 65.28% from 25.90m to 42.81m while net income improved from a loss of 33.28m to a smaller loss of 24.54m.
| Gross margin | -- |
|---|---|
| Net profit margin | -114.11% |
| Operating margin | -123.55% |
| Return on assets | -42.31% |
|---|---|
| Return on equity | -80.46% |
| Return on investment | -66.27% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Pieris Pharmaceuticals Inc fell by 21.24m. Cash Flow from Financing totalled 19.80m or 46.24% of revenues. In addition the company used 53.82m for operations while cash from investing totalled 12.00m.
| Cash flow per share | -11.82 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 14.17 |
|---|---|
| Tangible book value per share | 14.17 |
More ▼
Balance sheet in USDView more
| Current ratio | 3.95 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
